Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs Sorafenib in Advanced HCC
NCT02576509Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2015
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Dec 2015; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02576509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576509.